

## CPT1A RABBIT PAB

货号: S216443

产品全名: CPT1A 兔多抗

基因符号: CPT1, CPT1-L, L-CPT1

**UNIPROT ID:** P50416 (Gene Accession - BC000185)

**背景:** The mitochondrial oxidation of long-chain fatty acids is initiated by the sequential action of carnitine palmitoyltransferase I (which is located in the outer membrane and is detergent-labile) and carnitine palmitoyltransferase II (which is located in the inner membrane and is detergent-stable), together with a carnitine-acylcarnitine translocase. CPT I is the key enzyme in the carnitine-dependent transport across the mitochondrial inner membrane and its deficiency results in a decreased rate of fatty acid beta-oxidation. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

**抗原:** Fusion protein of human CPT1A

**经过测试的应用:** ELISA, IHC

**推荐稀释比:** IHC: 25-100; ELISA: 1000-5000

**种属反应性:** Rabbit

**克隆性:** Rabbit Polyclonal

**亚型:** Immunogen-specific rabbit IgG


**纯化:** Antigen affinity purification

**种属反应性:** Human, Mouse, Rat


**成分:** PBS (without Mg<sup>2+</sup> and Ca<sup>2+</sup>), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

**研究领域:** Metabolism, Cancer, Cardiovascular


**储存和运输:** Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human colon cancer tissue using 216443(CPT1A Antibody) at a dilution of 1/20(Cytoplasm, Cell membrane).



In comparison with the IHC on the left, the same paraffin-embedded Human colon cancer tissue is first treated with the fusion protein and then with 216443(Anti-CPT1A Antibody) at dilution 1/20.



The image on the left is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using 216443(Anti-CPT1A Antibody) at a dilution of 1/20.



In comparison with the IHC on the left, the same paraffin-embedded Human esophagus cancer tissue is first treated with fusion protein and then with D220478(Anti-CPT1A Antibody) at dilution 1/20.



# Product Description

Pioneering GTPase and Oncogene Product Development since 2010

---